Clinical Trials Browser

Phase 1/2 × Panitumumab × 30 days × Clear all

NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma